539 related articles for article (PubMed ID: 31422205)
1. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
2. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
3. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
[TBL] [Abstract][Full Text] [Related]
4. HPV Meets APOBEC: New Players in Head and Neck Cancer.
Riva G; Albano C; Gugliesi F; Pasquero S; Pacheco SFC; Pecorari G; Landolfo S; Biolatti M; Dell'Oste V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573337
[TBL] [Abstract][Full Text] [Related]
5. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
7. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
8. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
9. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
11. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
12. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
14. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
Yang W; Lee KW; Srivastava RM; Kuo F; Krishna C; Chowell D; Makarov V; Hoen D; Dalin MG; Wexler L; Ghossein R; Katabi N; Nadeem Z; Cohen MA; Tian SK; Robine N; Arora K; Geiger H; Agius P; Bouvier N; Huberman K; Vanness K; Havel JJ; Sims JS; Samstein RM; Mandal R; Tepe J; Ganly I; Ho AL; Riaz N; Wong RJ; Shukla N; Chan TA; Morris LGT
Nat Med; 2019 May; 25(5):767-775. PubMed ID: 31011208
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
17. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
[TBL] [Abstract][Full Text] [Related]
18. Tumor immune microenvironment in head and neck cancers.
Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
[TBL] [Abstract][Full Text] [Related]
19. Personalized cancer vaccination in head and neck cancer.
Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
[TBL] [Abstract][Full Text] [Related]
20. Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
Farlow JL; Brenner JC; Lei YL; Chinn SB
Oral Oncol; 2021 Sep; 120():105420. PubMed ID: 34218062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
